Leptospira interrogans icterohaemorrhagiae in a patient with Crohn's disease.
Katsanos
Konstantinos H
KH
Katopodis
Konstantinos P
KP
Kosmidou
Maria
M
Siamopoulos
Konstantinos C
KC
Tsianos
Epameinondas V
EV
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D002443:Ceftriaxone / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D041383:Leptospira interrogans serovar icterohaemorrhagiae / Q000302:isolation & purification*; D007922:Leptospirosis / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D002443:Ceftriaxone; D000069285:Infliximab; D000637:Transaminases